Home Companies Catalysts Deep Dives
Darzalex daratumumab APPROVED
Drug Profile
ModalityAntibody
RouteIV
Therapy AreaOncology
Launch2015-11-16
US LOE2029-06-01
Peak Sales Est$20300M
Formulations[{"id":"darzalex-iv","route":"IV","setting":"INFUSION_CENTER","frequency":"Weekly to monthly","is_pr
Companies
JNJ (LICENSEE)0%
GMAB (ROYALTY)0%
Mechanism: Anti-CD38
Expert: Monoclonal antibody targeting CD38 with enhanced ADCC activity.
Everyday: Targets a protein on the surface of certain immune and cancer cells.
Targets: ["CD38"]
Revenue History
PeriodRevenue ($M)
2025$14,351M
Q4 2025$3,900M
2024$11,670M
Programs (3)
IndicationStageKey StudyRegional Status
1L MMAPPROVEDMAIA, CASSIOPEIA, GRIFFIN[{"stage":"APPROVED","region":"US","approval_date":"2019-09-26"},{"stage":"APPRO
R/R MMAPPROVEDSIRIUS, CASTOR, POLLUX[{"stage":"APPROVED","region":"US","approval_date":"2015-11-16"},{"stage":"APPRO
AL amyloidosisAPPROVEDANDROMEDA[{"stage":"APPROVED","region":"US","approval_date":"2021-01-15"}]
Upcoming Catalysts (1)
Darzalex - MM - Bispecific Combo Data 2026
Notes
Best-in-class anti-CD38 for multiple myeloma. 2025 net sales $14.4B globally. Genmab receives tiered royalties (mid-teens to low-20s%). SC formulation (Darzalex Faspro) growing. Standard of care in 1L and R/R MM.
Data from Supabase · Updated 2026-03-24